Combination Approaches Combat Resistance to Endocrine Therapy in HR+ Breast Cancer
March 17th 2017
Genomic studies have made significant advancements in discovering methods to combat resistance to endocrine therapy in patients with hormone receptor (HR)–positive breast cancer over the past few years, according to Ian E. Krop, MD, PhD. Of particular interest are combination therapies blocking multiple driver pathways and resistance mechanisms.